CardioSAVE

Objective:

This project aims to develop a novel early stage prognostic test for clinical outcome in acute myocardial infarction (AMI) patients receiving percutaneous coronary intervention (PCI). This novel test will also be able to monitor treatment response. The tool will be based on (i) a unique set of biomarkers recently discovered by the cardiovascular research group at the Luxembourg Hospital center and for which Firalis controls the intellectual property and (ii) a novel set of markers to be selected using transcriptomic and protein discovery approaches (iii) Biomarkers candidates from another ongoing study (Fibrotargets) focused on cardiac infarct, included to increase the performance of the test. Firalis will collaborate with the SME Scienion (Germany) to translate these novel biomarkers into an actual in vitro diagnostic medical device. For the development and clinical validation of the device, these SMEs will collaborate with university hospitals: the Bad Krozingen Heart Center (Germany) and the leading research institute for genetic and molecular cell biology (IGBMC).

www.cardio-save.com

Duration: 2014-...

Program type:

Involved Partners: